Europe IP Manager
About the job
- A bachelor's degree in Law, Pharmacy, Chemistry, Life Sciences, or Biotechnology.
- At least 10 years of progressive experience in intellectual property management within the pharmaceutical or life sciences industry.
- Proficiency in interpreting intellectual property laws in Europe.
- Proven experience handling European intellectual property portfolios.
- Hands-on experience supporting business-to-business pharmaceutical deals, including licensing-in and licensing-out, distribution and supply agreements, co-development, and strategic partnerships.
- Strategic thinking with strong execution capability.
- Clear communication of complex intellectual property concepts to non-legal stakeholders.
- Define and execute European intellectual property strategy aligned with company objectives.
- Manage patent filings, prosecution, maintenance, and renewals.
- Conduct patent invalidation studies and prepare oppositions.
- Assess patent landscapes and competitive positioning.
- Support business development during deal evaluation, due diligence, term sheet and contract negotiations, and product development.
- Advise on exclusivity or non-exclusivity, territory rights, and intellectual property strategies for early market opportunities.
- Monitor third-party activities and analyze competitors’ patent portfolios.
- Report on risks and opportunities, including field-of-use limitations.
- Review and negotiate intellectual property-related clauses in licensing agreements, supply and distribution contracts, and confidentiality and data-sharing agreements.
- Ensure intellectual property ownership, background intellectual property, and foreground intellectual property are clearly defined.
- Assist in responding to patent litigation or regulatory queries as required.
- Conduct or coordinate freedom-to-operate analyses.
- Identify infringement risks and propose mitigation plans.
- Support litigation-avoidance strategies.
- Work closely with Business Development, Portfolio, Legal, Regulatory Affairs, and Research and Development.
- Manage external intellectual property counsel and consultants.
About the company
EVA Pharma develops and manufactures affordable medicines for global markets, focusing on 12 therapeutic areas such as anti-infectives, metabolic health, oncology, and pediatrics. It operates four manufacturing facilities with a 5,000-strong team and produces over one million healthcare products daily. The company runs two regional research centers that use AI-driven prediction and mRNA R&D to develop biological products and first-of-its-kind capabilities in the Middle East and Africa. EVA Pharma distributes its products to more than 60 countries and seeks to expand access to high-quality medicines worldwide. Its differentiation comes from its scale, regional R&D capabilities, and commitment to sustainable access, aiming to meet pressing, unmet disease needs with reliable supply.
Company Size
1,001-5,000
Company Stage
N/A
Total Funding
N/A
Headquarters
Al Sharikat, Egypt
Founded
1997
Get referred to Eva Pharma
See people who can refer or advise you
Simplify's Take
What believers are saying
- Egypt’s December 2024 insulin approval opens exportable manufacturing revenues and credibility with regulators.
- November 2025 EVA Pharma Oncology targets 22 million packs annually, with 11 more treatments planned.
- Access-heavy partnerships with Gilead, BeiGene, and Porton create multiple near-term revenue streams.
What critics are saying
- Gilead’s generic lenacapavir supply starts 2027, so execution delays destroy EVA Pharma’s moat.
- Oncology launches need Egypt market uptake; BRUKINSA, TEVIMBRA, and seven in-house products face entrenched competitors.
- Any FDA, EDA, or Gilead tech-transfer setback blocks EVA Pharma’s pivot into high-value biologics.
What makes Eva Pharma unique
- Egypt’s 2024 Lilly insulin approval proves EVA Pharma can localize complex biologics manufacturing.
- The 2024 Gilead lenacapavir license makes EVA Pharma Africa’s sole local generic producer.
- The 2025 BeiGene deal and 2025 Porton MOU extend EVA Pharma beyond generics into oncology and CAR-T.
Help us improve and share your feedback! Did you find this helpful?
Benefits
- Hybrid Work Options